Drug Trial Radar · NCT06392074
A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
Last checked: Nov 20, 2026Latest source record: Sep 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Mar 7, 2024
Primary completion
May 12, 2025
Study completion May 12, 2025
Sponsor
- Lead sponsor
- mAbxience Research S.L.Industry
- Sponsor type
- Industry
- First posted
- Apr 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, three-part, two-sequence per part, two-period, single-dose, cross-over study in healthy male volunteers to compare the PK, safety, and immunogenicity of MB04 and EU /US Enbrel®. During the course of the study, the similarity in pharmacokinetics will be assessed by sampling the levels of drug in the blood, and by comparing these levels among the different administration arms. Safety, tolerability, and immunologic response to the administered drugs will also be evaluated throughout.
Conditions
- Healthy Volunteers
Interventions
MB04Drug
Subcutaneous injection
US License EnbrelDrug
Subcutaneous injection
EU Source EnbrelDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the serum concentration versus time curve (AUC) from time zero to infinity (AUC0-inf)Time frame: Day 1 to day 62
- Maximum observed serum concentration (Cmax)Time frame: Day 1 to day 62
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Clinical Research Unit
Groningen, Provincie Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.